Mitomycin Medac (Mitomycin)

Mitomycin functions as a DNA cross‑linking alkylating agent. After activation inside the cell, it forms covalent bonds with DNA bases, preventing replication and transcription, which leads to programmed cell death of rapidly dividing cancer cells.

The dosage of Mitomycin Medac is individualized by the prescribing oncologist based on the specific cancer type, treatment regimen, patient weight, renal function, and prior therapy. Only a qualified healthcare professional should determine the appropriate dose.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended while receiving Mitomycin, as the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mitomycin is distinct for its ability to form DNA cross‑links under hypoxic conditions, making it effective in certain solid tumors where other alkylators may be less active. Compared with agents like cyclophosphamide, Mitomycin often requires careful renal monitoring and has a unique intravesical application for bladder cancer.

Mitomycin Medac should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required and inspect for particulate matter.

Mitomycin Medac is supplied as a sterile solution for intravenous infusion or intravesical instillation. Intravenous dosing is given over a set period under clinical supervision, while intravesical administration involves instilling the solution directly into the bladder after tumor resection.

The most serious risks include severe bone‑marrow suppression leading to infection or bleeding, pulmonary toxicity such as interstitial pneumonitis, renal failure, and rare but life‑threatening hemolytic‑uremic syndrome. Prompt monitoring and early detection of symptoms are essential.

Mitomycin should not be used in patients with known hypersensitivity to the drug, severe renal impairment, active uncontrolled infections, or in pregnant and breastfeeding women. Caution is also advised for individuals with pre‑existing pulmonary disease or those receiving other myelosuppressive therapies.